证券代码：600252 证券简称：中恒集团 公告编号：临 2025-79 广西梧州中恒集团股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 股东大会召开日期：2025年9月29日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 一、 召开会议的基本情况 (一) 股东大会类型和届次 2025年第二次临时股东大会 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相 结合的方式 (四) 现场会议召开的日期、时间和地点 召开的日期时间：2025 年 9 月 29 日 10 点 00 分 召开地点：广西南宁市江南区高岭路 100 号办公楼会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 9 月 29 日 至2025 年 9 月 29 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大 ...

证券代码：600252 证券简称：中恒集团 公告编号：临 2025-78 广西梧州中恒集团股份有限公司 第十届董事会第三十一次会议决议公告 二、董事会会议审议情况 会议审议并以记名投票方式表决通过以下议案及事项： （一）会议审议通过《广西梧州中恒集团股份有限公司关于提名李骅先生为 公司第十届董事会独立董事候选人的议案》； 鉴于独立董事李俊华先生因连续任职已满六年，辞去公司第十届董事会独立 董事及董事会专门委员会相关职务。根据《上市公司独立董事管理办法》《公司章 程》等相关规定，经公司董事会提名委员会审查，董事会同意提名李骅先生为公 司第十届董事会独立董事候选人（独立董事候选人简历详见本公告附件）。李骅 先生已取得独立董事资格证书，其兼任境内上市公司独立董事未超过 3 家（含本 次提名）。独立董事任期自股东大会审议通过之日起至第十届董事会届满之日止。 在公司股东大会选举产生新任独立董事之前，李俊华先生将继续履行独立董 事及专门委员会相关职责。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 广西梧州中恒集 ...

Core Insights - The company emphasizes technological innovation as a core engine for growth, focusing on research system reform and major project breakthroughs to create a comprehensive innovation ecosystem [1] Group 1: Innovation and Development - The company has developed a Class 1 innovative traditional Chinese medicine, "Sanqi Granules," which received clinical trial approval from the National Medical Products Administration in April 2023, aiming to enter Phase II and III studies for chronic glomerulonephritis patients [1] - The subsidiary, Laimei Pharmaceutical, achieved significant results, ranking in the top 50 of the "2024 China Innovative Drug Value Ranking Comprehensive Strength List" [1] - The global first nano carbon iron project undertaken by the subsidiary Sichuan Yingrui Pharmaceutical is progressing steadily, with the nano carbon suspension injection entering the international stage and being selected as one of Chongqing's first batch of iconic future industry products [1] Group 2: Collaboration and Research - The company focuses on deep integration of production, education, and research, promoting the development of ASEAN characteristic medicinal materials and traditional Chinese medicine innovation [1] - A joint application with Shanghai University of Traditional Chinese Medicine for the "Modernization of Traditional Chinese Medicine" national key research and development plan has been successfully approved, aiding in the establishment of a quality control standard system for traditional Chinese medicine [1] Group 3: Achievements and Recognition - The company has been approved for 7 national and provincial-level research projects, receiving nearly 3 million yuan in financial subsidies [1] - The project "Research and Development Application Demonstration of the 'Nature-Effect-Material' Theory of Traditional Chinese Medicine and Ethnic Medicine," in collaboration with universities, won the second prize of the 2024 Guangxi Science and Technology Progress Award [1] - The company has established 22 provincial and ministerial-level research platforms, holds over 340 effective patents, with nearly 70% being invention patents, and has received 7 China Patent Awards for excellence and 8 Guangxi Invention Creation Exhibition Awards, reinforcing its technological barriers [1]

Group 1 - The core point of the article is the announcement of a bidding project by Guangxi Guangtou Smart Service Group Co., Ltd. for comprehensive logistics services in the Liuzhou area, with a budget of 1 million yuan [1] - The bidding information was released on September 2, 2025, indicating a future project timeline [1] - The ownership structure of Guangxi Guangtou Smart Service Group shows that it is held by China Merchants Jiyu and Zhongheng Group, with respective shareholding ratios of 40% and 5% [1]

Group 1 - The core viewpoint of the articles highlights that Zhongheng Group has achieved revenue growth and profit increase in the first half of 2025, driven by market expansion, R&D innovation, and diversified layout [1][2] - In the first half of 2025, Zhongheng Group reported a revenue of 1.451 billion yuan, a year-on-year increase of 2.84%, and a net profit attributable to shareholders of 27.08 million yuan, up 23.59% [1] - The pharmaceutical manufacturing segment generated an external revenue of 1.044 billion yuan, reinforcing the company's revenue base [1] Group 2 - Zhongheng Group is focusing on innovation and product layout to establish a new growth curve, optimizing its R&D system and signing cooperation agreements with key laboratories [2] - The company has received clinical trial approval for its innovative drug project "Sanqi Granules" and has introduced a candidate drug molecule for chronic heart failure, expanding market opportunities in chronic kidney disease and cardiovascular fields [2] - The health consumption segment has launched 26 new products, contributing to steady revenue and profit growth [2] Group 3 - Zhongheng Group repurchased 118 million shares for 301 million yuan, accounting for 3.56% of the total share capital, reflecting management's confidence in future development [3] - The company's subsidiary, Laimei Pharmaceutical, has developed "Injectable Esomeprazole Sodium," recognized as a major technological innovation product in Chongqing for 2024, addressing key technical challenges in synthesis and freeze-drying stability [3] - This innovation not only breaks the import monopoly but also provides better medication options for patients, showcasing the company's strength in formulation R&D and production process innovation [3]

Core Insights - Zhongheng Group reported a revenue of 1.451 billion yuan for the first half of 2025, representing a year-on-year increase of 2.84%, while net profit attributable to shareholders reached 27.08 million yuan, up 23.59% year-on-year, and net profit after deducting non-recurring gains and losses was 24.83 million yuan, showing a significant increase of 196.24% [1][2] Group 1 - The company strengthened market expansion efforts and increased investment in R&D, leading to growth in both revenue and net profit [1] - Zhongheng Group focused on its core pharmaceutical manufacturing business, maintaining market share for key products, with sales of injectable thrombolytic agents and traditional Chinese medicine products both showing year-on-year growth [1][2] Group 2 - The company optimized its R&D system and established incentive management measures, signing cooperation agreements with key laboratories to enhance innovation capabilities [2] - Zhongheng Group concentrated on key therapeutic areas such as cardiovascular and chronic kidney disease, advancing key research projects and new drug initiatives [2] Group 3 - The company utilized the natural advantages of Guangxi's specialty medicinal materials, showing strong market potential in health consumption and daily chemical beauty sectors, with a product matrix already established [2] - In the health consumption sector, the subsidiary launched 26 new products, while the daily chemical beauty sector developed a dual innovation matrix combining technology and products [2] Group 4 - To protect the interests of the company and its investors, Zhongheng Group repurchased shares worth 301 million yuan, totaling 118 million shares, which accounted for 3.56% of the total share capital, completed on August 27 [3]

Core Insights - Zhongheng Group (600252) reported a year-on-year increase in both revenue and net profit for the first half of 2025, with total revenue reaching 1.451 billion yuan, up 2.84%, and net profit attributable to shareholders at 27.08 million yuan, up 23.59% [1] Financial Performance - Total revenue for Q2 2025 was 709 million yuan, reflecting a 17.18% increase year-on-year [1] - Q2 net profit attributable to shareholders was 8.81 million yuan, showing a significant increase of 126.86% year-on-year [1] - Gross margin decreased to 30.29%, down 24.11% year-on-year, while net margin fell to 0.53%, down 67.38% [1] - Total expenses (selling, administrative, and financial) amounted to 362 million yuan, accounting for 24.94% of revenue, a decrease of 32.08% year-on-year [1] - Earnings per share remained at 0.01 yuan, with a year-on-year increase of 28.12% [1] Balance Sheet Changes - Cash and cash equivalents increased by 29.39% to 4.132 billion yuan [1] - Accounts receivable rose by 10.27% to 860 million yuan [1] - Interest-bearing debt increased by 18.37% to 2.278 billion yuan [1] Cash Flow Analysis - Operating cash flow showed a significant decline of 132.23%, attributed to a decrease in sales receipts [7] - Financing cash flow increased by 309.33%, indicating a larger scale of external financing [8] Operational Insights - The company’s business model relies heavily on marketing, necessitating a thorough examination of the underlying drivers of this approach [15] - Historical data indicates a weak return on invested capital (ROIC), with a median of 5.49% over the past decade and a particularly poor ROIC of -6.05% in 2024 [13]

Group 1 - The core point of the article is that Zhongheng Group reported a decrease in the number of shareholders and an increase in average shareholding quantity, while its average shareholding value remains below the industry average [1][2] - As of June 30, 2025, Zhongheng Group had 114,893 shareholders, a decrease of 7,404 shareholders or 6.05% from March 31, 2025 [1][2] - The average number of shares held per shareholder increased from 27,400 shares to 28,800 shares, with an average shareholding value of 73,000 yuan [1][2] Group 2 - In the Chinese medicine industry, Zhongheng Group's number of shareholders is above the industry average of 52,500 shareholders as of June 30, 2025 [1] - The average shareholding value for A-share listed companies in the Chinese medicine industry is 245,400 yuan, which is significantly higher than Zhongheng Group's average [1] - From March 31, 2025, to June 30, 2025, Zhongheng Group's stock price increased by 7.2%, despite the reduction in the number of shareholders [1][2] Group 3 - During the period from March 31, 2025, to June 30, 2025, the net outflow of main funds for Zhongheng Group was 17.01 million yuan, while retail investors contributed a net inflow of 13.19 million yuan [2] - The stock price fluctuations over the previous quarters show varying trends, with a notable increase of 10.14% from September 30, 2024, to December 31, 2024 [2]

Core Viewpoint - The report highlights the financial performance and operational strategies of Guangxi Wuzhou Zhongheng Group Co., Ltd. for the first half of 2025, emphasizing growth in net profit and strategic initiatives in the pharmaceutical and health sectors [1][2]. Company Overview and Financial Indicators - The company reported a total revenue of approximately 1.45 billion yuan, representing a 2.84% increase compared to the same period last year [2]. - The total profit decreased by 19.38% to approximately 27.73 million yuan, while the net profit attributable to shareholders increased by 23.59% to approximately 27.08 million yuan [2]. - The net cash flow from operating activities showed a significant decline of 132.23%, amounting to approximately -69.18 million yuan [2]. - As of June 30, 2025, the total assets reached approximately 11.03 billion yuan, a slight increase of 0.49% from the end of the previous year [2]. Business Operations - Zhongheng Group focuses on pharmaceutical manufacturing, with nine key subsidiaries, including Wuzhou Pharmaceutical, which specializes in traditional Chinese medicine [3][4]. - The company aims to enhance the quality of life through its mission of "producing quality Chinese medicine to protect public health" [3][4]. - Wuzhou Pharmaceutical has a rich history and is recognized as a leading enterprise in the production of traditional Chinese medicine, holding numerous production approvals and patents [3][4]. Industry Context - The pharmaceutical manufacturing industry in China faced challenges in the first half of 2025, with a slight decline in revenue and profit among large-scale enterprises [9]. - The aging population in China is expected to drive demand for healthcare products, with projections indicating that the population aged 65 and above will reach 220 million by the end of 2024 [9]. - The industry is undergoing structural changes, with a focus on innovation and international expansion as key growth drivers [10]. Strategic Initiatives - The company is actively pursuing innovation in drug development and has established a comprehensive research and development framework to support new product launches [17]. - Zhongheng Group is enhancing its marketing strategies and expanding its distribution channels to improve market penetration and sales performance [16][17]. - The company has implemented a three-pronged development strategy focusing on sales-driven revenue growth, investment optimization, and strengthening research capabilities [14][15].

| 广西梧州中恒集团股份有限公司2025 | | 年半年度报告摘要 | | | | --- | --- | --- | --- | --- | | 公司代码：600252 公司简称：中恒集团 | | | | | | 广西梧州中恒集团股份有限公司 | | | | | | 广西梧州中恒集团股份有限公司2025 年半年度报告摘要 | | | | | | 第一节 重要提示 | | | | | | 展规划，投资者应当到 www.sse.com.cn 网站仔细阅读半年度报告全文。 | | | | | | 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | | | | | | 无 | | | | | | 第二节 公司基本情况 | | | | | | 公司股票简况 | | | | | | 股票种类 股票上市交易所 股票简称 | | 股票代码 | | 变更前股票 | | 简称 | | | | | | A股 上海证券交易所 中恒集团 | | 600252 | | 无 | | 联系人和联系方式 董事会秘书 | | | | 证券事务代表 | | 姓名 王海润 | | 冯卢璐 | | | | 电话 0771 ...